EVH · Evolent Health, Inc · Stock research

The narrative is accelerating — dated by the 2026-08-06 print reaction (shares +18.2% on the session after gapping 27.3% in the premarket to $3.92), five sell-side target moves to $6 between 2026-08-10 and 2026-08-18, and the 2026-08-14 Tiger Global 13F. The counterweight sits in the same tape: RSI(14) reached 84.8 at the 2026-08-21 close of $4.74, and the company calendar is empty until the Q3 print.

EVH — Evolent Health, Inc.

Current Thesis

The binary this dossier tracked through July resolved on 2026-08-06 and resolved well on revenue: Q2 revenue $652.5M against $444.3M a year earlier and a ~$598M consensus, adjusted EPS $0.02 versus a $(0.02) estimate, FY2026 revenue guidance lifted to $2.6–2.7B from $2.4–2.6B, and a new oncology Performance Suite partnership covering 1.5M lives across 11 states at roughly $300M of annualized revenue, targeted to launch by December 2026 pending regulatory approvals.

What has changed since is the shape of the bid. The advance did not start from the levels this note was writing about in July — the shares gapped up 27.3% in the 2026-08-06 premarket to $3.92, and Citigroup's 2026-08-11 upgrade explicitly framed itself as a call after a ~30% selloff. So a meaningful part of the move to the 2026-08-21 close of $4.74 is repair of a pre-print de-rate rather than a fresh re-rating; the shares remain 52.6% below the 52-week high of $9.99.

The narrative leg an investor is buying now is margin, not revenue. The Q2 medical expense ratio was 95.3% against 80.0% a year earlier, and management pre-guided the direction on the 2026-08-06 call: MER higher again in Q3 on a full quarter of the Highmark launch, then roughly 250 basis points of gradual improvement by Q4, against a full-year 2026 MER target of approximately 93%. The Q3 print is therefore signposted to look worse before it looks better, and the graded item is whether the Q4 improvement and the ~93% full-year frame survive contact.

Bullish and bearish views on Evolent Health, Inc

The model's bull view on Evolent Health, Inc (EVH), in brief: Revenue $652.5M in Q2 2026 versus $444.3M in Q2 2025, ahead of the ~$598M consensus; GAAP net loss narrowed to $28.4M from $51.1M (2026-08-06 release). The bear view: Management guided Q3 2026 MER higher than Q2's 95.3% on the 2026-08-06 call. Both cases follow in full.

Bull Case

• Revenue $652.5M in Q2 2026 versus $444.3M in Q2 2025, ahead of the ~$598M consensus; GAAP net loss narrowed to $28.4M from $51.1M (2026-08-06 release).
• FY2026 revenue guidance raised to $2.6–2.7B from $2.4–2.6B with the adjusted EBITDA range tightened to $120–135M from $110–140M — the profit floor lifted, not merely the range widened.
• Performance Suite revenue reached $485M in Q2, driven by the Highmark launch and the earlier Aetna rollout (Q2 2026 slides).
• The oncology partnership — 1.5M lives, 11 states, ~$300M annualized, launch targeted by December 2026 — is the named contract under the 2027 statement of revenue growth above 25% and an adjusted EBITDA midpoint at or above $150M (2026-08-06 call).
• Sell-side direction reversed inside two weeks: Citigroup upgraded to Buy on 2026-08-11 having gone to Neutral on 2026-07-23; TD Cowen raised its target to $6 from $5 on 2026-08-17; J.P. Morgan reiterated Overweight and raised to $6 on 2026-08-18.
• Tiger Global disclosed 11,063,912 shares, a 99% increase, in the 13F published 2026-08-14 (holdings dated 2026-06-30).

Bear Case

• Management guided Q3 2026 MER higher than Q2's 95.3% on the 2026-08-06 call. The next reported quarter is pre-committed to a worse margin print, and the ~250bp Q4 improvement is a forecast, not a delivered result.
• Cost of revenue rose 66.2% against a 46.9% revenue increase in Q2; adjusted EBITDA fell to $28.1M (4.3% margin) from $37.5M (8.5%) while revenue grew roughly 47%.
• Simply Wall St's trailing-twelve-month aggregation puts the net loss at $511.06M as of Q2 2026 against $185.19M a year earlier.
• The target distribution has collapsed onto one number. Canaccord (Buy, 2026-08-10, from $7), Citigroup (Buy, 2026-08-11, from $6.75), Truist (Hold, 2026-08-12, from $7), TD Cowen (Buy, 2026-08-17, from $5) and J.P. Morgan (Overweight, 2026-08-18) all sit at $6.
• $115.7M cash against $966.5M net long-term debt at 2026-06-30, plus planned 2026 capitalized software spend of $25–30M. The equity is the levered residual on small EBITDA changes, and a 50%-plus advance is the window in which issuance becomes cheapest for the company.
• The 2027 revenue anchor has not launched and requires regulatory approval; nothing in the Q2 disclosure converts it to live business.

Setup & Price Structure

The 2026-08-21 close of $4.74 sits about 21% above the $3.92 level the shares touched in the 2026-08-06 premarket, and roughly 27% below the $6 target every updating desk now carries. Three-month price change is +20.0%; distance from the 52-week high of $9.99 is -52.6%.

RSI(14) at 84.8 is the stretched reading here — a name that has run this far in eleven sessions off a post-selloff low, with no company-confirmed event on the calendar before the Q3 report. Crowding observables, stated as observables: five target revisions clustered into nine sessions (2026-08-10 to 2026-08-18); no desk above $6, so the sell-side has spent its upside surprise unless someone breaks the cluster; the Tiger Global position is dated 2026-06-30 and disclosed 2026-08-14, meaning it was accumulated before the print and tells nothing about post-print flow; the recent filings feed shows no Form 4 activity. Whether the advance is absorbed depends on holding the 2026-08-06 earnings gap — the zone around $4.00 marks both a full give-back of the post-print advance and roughly the midpoint of the August leg.

Catalyst Calendar (next 30 days)

• 2026-08-23 to 2026-09-22 — nothing company-confirmed. As of 2026-08-23 the Evolent investor-relations events page lists no September 2026 conference participation; the last such announcement, dated 2026-02-26, covered the Cowen 46th Annual Healthcare Conference on 2026-03-03 and Oppenheimer's on 2026-03-17. An interim datapoint on the cost trend would have to arrive via a conference appearance or an 8-K.
• ~2026-11-01 (est.) — ACA open enrollment for plan year 2027 begins. Exchange attrition was a named 2027 headwind on the 2026-08-06 call and the stated reason behind Citi's 2026-07-23 downgrade before the same desk reversed on 2026-08-11.
• ~2026-11-05 (est.) — Q3 2026 results. Not announced as of 2026-08-23; Q3 2025 landed 2025-11-06.
• 2026-12-31 — targeted launch of the 1.5M-life, 11-state oncology Performance Suite contract (~$300M annualized), pending regulatory approvals.

What Would Change Our Mind

The entire structure dates to one session. If the 2026-08-06 earnings gap is filled and the shares trade back into the pre-print zone, the market has re-read the raise as revenue bought with underwriting risk — the exact reading the 95.3% MER and the year-over-year EBITDA decline already support. A weekly close below $4.00 is the gradeable version of that.

Three non-price conditions carry the same weight. First, the Q3 print (~2026-11-05) landing with MER above 95.3% and no reaffirmation of either the ~250bp Q4 improvement or the ~93% full-year target — the guided path failing on its first checkpoint. Second, the December 2026 oncology launch date moving in an 8-K or on the Q3 call, which removes the only dated support under the 2027 growth statement. Third, any of the five desks now at $6 cutting back below it, or an equity/convertible issuance announced into this advance.

The condition that would strengthen the case rather than break it: a desk moving above $6, or a company disclosure between now and November that shows the Highmark cohort's cost load running at or below plan.

Correlation Notes

• Evolent's Performance Suite is a downstream taker of the same specialty and oncology cost trend that sets managed-care MLRs. UNH, ELV, HUM and CNC guidance revisions on medical cost trend read through directly, and a peer MLR headline has historically moved EVH double digits with no company news — the 2026-07-23 analyst action alone took the shares down 13% to $4.81 in one session.
• The revenue ramp is contract-specific: Highmark (launched into Q2 2026) and Aetna/CVS (earlier rollout) are the two named drivers of both the $485M Performance Suite quarter and the MER load. CVS commentary on specialty cost trend is the closest external proxy for Evolent's Q3 margin.
• Medicaid redetermination and ACA exchange attrition were both cited by management on 2026-08-06 as headwinds embedded in the 2027 outlook, tying the name to policy flow rather than to sector risk appetite.
• With $966.5M net long-term debt against $115.7M cash, the equity behaves as a levered small-cap option on EBITDA; it moves with rates and risk appetite more than a $2.6–2.7B revenue base would imply, and it is not correlated to the AI/health-tech complex despite the "health technology" label.